To evaluate the impact of baseline left ventricular ejection fraction (LVEF) and its interaction with low-gradient aortic stenosis (LGAS) on all-cause mortality after transfemoral aortic valve implantation (TF-TAVI).
| INTRODUC TI ON
Almost half of the patients with symptomatic severe aortic valve stenosis (AS) who undergo transcatheter aortic valve implantation (TAVI) may have an impaired left ventricular ejection fraction (LVEF).
1 Many observational studies [2] [3] [4] and meta-analyses [5] [6] [7] found that these patients are at increased risk of mortality after TAVI.
Nevertheless, the degree of impairment of LVEF that is associated with an increased mortality at short and mid-term follow-up remains poorly defined, as most of these studies dichotomized LVEF only to normal and abnormal and used different thresholds to define an abnormal LVEF in their analyses. 3, 4, [8] [9] [10] The American Society of Echocardiography (ASE) and the European Association for Cardiovascular Imaging (EACVI) have proposed a classification for LVEF into normal (>51% in male and >53% in female), mildly abnormal (>40%-51% in male and to 53% in female), moderately abnormal (≥30%-≤40%), and severely abnormal (<30%) thus including different thresholds for males and females. 11 This distinction might be of clinical significance, given the predominance of female patients in most TAVI registries 2, 12 and also considering the usually better outcome of female patients. 13 However, the clinical value of this classification for expanded risk stratification based on baseline LVEF has not been studied in patients undergoing TAVI.
Moreover, abnormal LVEF in patients with severe AS is associated with an increased prevalence of a low-gradient severe aortic stenosis (LGAS), that is, a small aortic valve area (<1.0 cm 2 ) consistent with severe AS but a low mean transvalvular aortic gradient (<40 mm Hg)
consistent with non-severe AS. 14 This condition has been previously reported to be associated with a less favorable outcome after TAVI compared to severe AS with high gradients. 15 However, the interaction between different degrees of abnormal LVEF and LGAS has not been thoroughly investigated so far.
Accordingly, we sought to evaluate the prognostic impact of baseline LVEF, classified according to current ASE/EACVI recommendations, on 30-day and 1-year all-cause mortality after transfemoral TAVI (TF-TAVI) and the interaction between LGAS and LVEF.
| ME THODS

| Patient population and TF-TAVI procedure
We retrospectively analyzed clinical data of all patients with severe AS who underwent TF-TAVI at the West German Heart and Vascular LGAS if the mean transvalvular aortic pressure gradient at baseline was <40 mm Hg with an aortic valve area <1.0 cm 2 .
14 Mitral regurgitation severity and aortic regurgitation severity were obtained from TTE reports and graded according to the current guideline for the management of valvular heart diseases. Reasons for exclusion were as follows: baseline TTE-studies performed in the referring hospital only (57 patients), poor TTE quality (one patient), TF-TAVI for degenerated bioprosthesis (20 patients),
| Statistical analysis
for native aortic regurgitation (two patients) or for the treatment of a stenotic bicuspid aortic valve (one patient) and abortion of the procedure in one patient due to a too large native aortic annulus.
Furthermore, four patients underwent two procedures: in two patients, the prosthesis could only be implanted on a second attempt due to the requirement of a larger prosthesis that was not available at the time of the initial procedure, which was excluded from the analysis. In the other two patients, staged valve-in-valve procedures (9) 25 (16) 24 (26) 13 (35) <0.001
TA B L E 1 Baseline patients' characteristics
Severe CKD 73 (12) 30 (9) 21 (13) 14 (15) Data are presented as count (percentages) or median (25th percentile, 75th percentile). BMI = body mass index; CABG = coronary artery bypass graft operation; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; LGAS = low-gradient aortic stenosis; LVEF = left ventricular ejection fraction; PCI = percutaneous coronary intervention; PPM/ICD = permanent pace maker/internal cardioverter defibrillator.
were performed due to severe paravalvular leakages and these were also excluded from the analysis. Baseline demographic and TTE findings of the study groups are summarized in Table 1 . The balloonexpandable prosthesis was implanted in 497 patients (80%), and the self-expandable prosthesis was implanted in 127 patients (20%).
| Echocardiographic data
Baseline LVEF was normal in 336 (53.8%), mildly abnormal in 160 (25.6%), moderately abnormal in 91 (14.6%), and severely abnormal in 37 (5.9%) patients, respectively. The prevalence of severely and moderately abnormal LVEF was more common in male patients, in patients with coronary artery disease and in patients with extracardiac arteriopathy. These patients had a higher EuroSCORE I and were more likely to have an implanted permanent pacemaker/ intracardiac cardioverter defibrillator than patients with normal and mildly abnormal LVEF. These data are summarized in Table 1 .
Mean transvalvular aortic gradients correlated significantly with the degree of LVEF impairment with increased prevalence of LGAS in patients with severely (29 patients, 78%) and moderately abnormal LVEF (54 patients, 59%) compared to patients with mildly abnormal (50 patients, 31%) and normal LVEF (114 patients, 34%; P < 0.001). Data are presented as count (percentage) or median (25th percentile, 75th percentile). BMI = body mass index; CABG = coronary artery bypass graft operation; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; LGAS = low-gradient aortic stenosis; LVEF = left ventricular ejection fraction; PCI = percutaneous coronary intervention; PPM/ICD = permanent pace maker/internal cardioverter defibrillator.
| Thirty-day and 1-year mortality
F I G U R E 1 One-year mortality in different left ventricular ejection fraction groups: *adjusted P is 0.002 compared to normal LVEF (blue), 0.001 compared to mildly abnormal LVEF (green), and 0.138 compared to moderately abnormal LVEF (red) F I G U R E 2 One-year mortality in patients with and without low-gradient aortic stenosis across the different groups of baseline left ventricular ejection fraction died at 1-year follow-up were less likely to be females (59 of 128 pa- LGAS was significantly greater than in those without LGAS (31% vs 11%, P = 0.022) in the moderately abnormal LVEF group and it was numerically greater than in those without LGAS in the severely abnormal LVEF group (48% vs 25%, P = 0.219; Figure 2 ).
When combining patients with normal and mildly abnormal LVEF in one group (LVEF >40%) and patients with moderately and severely abnormal LVEF in a second group (LVEF ≤40%), and comparing the outcome of patients with LGAS to those without LGAS in both groups, only patients with coexisting moderately/severely abnormal LVEF and LGAS exhibited greater 1-year mortality compared to other patients (37% vs 13% to 18% in other groups, adjusted P < 0.05). These data are summarized in Figure 3 . Mortality difference was also significant at 30-day follow-up.
Univariate predictors of 30-day and 1-year mortality are summarized in Table 3 . In a multivariate model including EuroSCORE I, moderately/severely abnormal LVEF, LGAS, chronic obstructive pulmonary disease, and diabetes mellitus, only EuroSCORE I was independently predictive of increased 30-day mortality (HR: 1.021, 95%
CI: 1.003-1.038, P = 0.021). After adding the predefined interaction term between moderately/severely abnormal LVEF and LGAS to this model, the coexistence of moderately/severely abnormal LVEF and
LGAS was the only independent predictor of increased 30-day mor- 
| D ISCUSS I ON
The main finding of this study is that moderately and severely abnormal LVEF (≤40%) at baseline is associated with increased mortality F I G U R E 3 One-year mortality in patients with normal/mildly abnormal left ventricular ejection fraction versus moderately/severely abnormal in the presence and absence of low-gradient aortic stenosis: *adjusted P is <0.001 compared to normal/mildly abnormal LVEF without LGAS (blue), 0.006 compared to normal/mildly abnormal LVEF with LGAS (green), and 0.024 compared to moderately/severely abnormal LVEF without LGAS (red)
after TF-TAVI, especially when the mean transvalvular aortic gradient is <40 mm Hg, while outcomes in patients with normal and mildly abnormal LVEF (>40%) are comparable regardless the pressure gradient across the aortic valve.
Intuitively, a reduced LVEF prior to TAVI appears to negatively impact short and mid-term mortality. However, previous data are not consistent, and the degree of LVEF impairment predicting a poor outcome remains poorly defined. Data from the German Aortic Valve Registry and the UK-TAVI Registry show that patients with a LVEF ≤30% experienced up to 2-fold increase of 1-year mortality compared to patients with a LVEF >30%.
2,23 Similar
observations were made in patients with a LVEF ≤35% compared to LVEF >35% in an observational study at two Italian TAVI centers. 24 Meanwhile, other mono-and multicentric observational studies found no outcome difference after TAVI in patients with a baseline LVEF ≤30% compared to those with a baseline LVEF >30% 8,10 or in patients with LVEF >45% compared to LVEF ≤45%, 9 but patients with LVEF <30% who were treated medically had a significantly greater mortality on long-term follow-up compared to those who undergone TAVI. Overall, meta-analyses of observational studies show that any impairment of LVEF (<50%) is associated with increased 1-year BMI = body mass index; CABG = coronary artery bypass graft operation; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; LGAS = low-gradient aortic stenosis; LVEF = left ventricular ejection fraction; PCI = percutaneous coronary intervention; PPM/ICD = permanent pace maker/internal cardioverter defibrillator.
TA B L E 3 Univariate Cox regression analysis mortality after TAVI. [5] [6] [7] Our results confirm the prognostic value of an impaired LVEF after TF-TAVI. Nevertheless, we observed this negative impact of impaired LVEF on outcome after TF-TAVI only in patients with moderately/severely abnormal LVEF (<40%), whereas patients with mildly abnormal LVEF had still favorable outcome after TF-TAVI.
The LVEF-based risk stratification of patients undergoing TF-TAVI could be further refined by accounting for LGAS, a condition that is classically described in patients with impaired LVEF and attributed to low flow across the stenotic aortic valve, but may also be seen in patients with normal LVEF in the presence of considerable left ventricular hypertrophy with small left ventricular cavity and in patients with increased arterial stiffness. 14 Our data show that
LGAS is an independent predictor of 1-year mortality after TAVI and that its interaction with baseline LVEF is significant. Only the subgroup of patients with coexistent moderately/severely abnormal LVEF and LGAS showed increased 30-day and 1-year mortality after TF-TAVI, whereas mortality rates in patients with moderately/ severely abnormal LVEF without LGAS were comparable to patients with normal/mildly abnormal LVEF. Several recent studies and a contemporary meta-analysis 25 have underlined the additive prognostic value of LGAS to LVEF in patients undergoing TAVI. The impact of LVEF and transvalvular aortic gradients on outcome after TAVI was investigated in 764 consecutive patients from a multicenter dataset. Similar to our findings, the combination of LGAS with a LVEF <40% was predictive of increased mortality (HR: 2.4) at a median follow-up of 396 days after TAVI. 4 Patients with a classical low-flow low-gradient severe AS (ie, LVEF ≤30%, mean transvalvular aortic gradient ≤40 mm Hg) were found to have an increased 30-day and 1-year mortality after TAVI. One-year mortality in this subgroup was 38% in one study, 26 which is similar to the 1-year mortality of 37% seen in our patients with moderately/severely abnormal LVEF and
LGAS. Likewise, in the UK-TAVI registry, abnormal LVEF (<50%) was associated with an increased mortality at 2-year follow-up after TAVI only in patients with low-gradient AS (defined as a peak transvalvular aortic gradient <64 mm Hg), while in the subgroup of patients with normal LVEF, there was no difference in 2-year mortality after TAVI in patients with LGAS and those with high gradients. In multivariate analysis, only LGAS was associated with increased 1-year mortality after TAVI with no modifying effect of LVEF on outcome. 27 One third of the patients have undergone a transapical TAVI with no dedicated subgroup analysis of TF-TAVI data, which may account for different results from ours. In summary, we found that moderately/severely abnormal LVEF (≤40%) at baseline is associated with increased mortality after TF-TAVI, especially when the mean transvalvular aortic gradient is <40 mm Hg, while outcomes in patients with normal and mildly abnormal LVEF are comparable regardless the pressure gradient across the native aortic valve.
| LI M ITATI O N S
Our study has the inherent limitations of observational reports. In addition, data on stroke volume, and hence, flow state across the stenotic aortic valve were not collected. Low flow is an independent outcome predictor after TAVI. 35 LGAS was, however, previously used as an approximation for low-flow state.
3 Stress echocardiography was not performed in patients with combined abnormal LVEF and LGAS for further risk stratification, data on postprocedural outcomes (eg, postprocedural aortic regurgitation >I°) were missing and cardiovascular mortality was not assessed.
| CON CLUS ION
Moderately/severely abnormal LVEF (≤40%) at baseline is associated with increased mortality after TF-TAVI, especially when the mean transvalvular aortic gradient is <40 mm Hg, while outcomes in patients with normal and mildly abnormal LVEF are comparable regardless the pressure gradient across the native aortic valve.
